These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

505 related articles for article (PubMed ID: 22745588)

  • 21. Resistance to EGF receptor inhibitors in glioblastoma mediated by phosphorylation of the PTEN tumor suppressor at tyrosine 240.
    Fenton TR; Nathanson D; Ponte de Albuquerque C; Kuga D; Iwanami A; Dang J; Yang H; Tanaka K; Oba-Shinjo SM; Uno M; Inda MM; Wykosky J; Bachoo RM; James CD; DePinho RA; Vandenberg SR; Zhou H; Marie SK; Mischel PS; Cavenee WK; Furnari FB
    Proc Natl Acad Sci U S A; 2012 Aug; 109(35):14164-9. PubMed ID: 22891331
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Discovery and Therapeutic Exploitation of Mechanisms of Resistance to MET Inhibitors in Glioblastoma.
    Cruickshanks N; Zhang Y; Hine S; Gibert M; Yuan F; Oxford M; Grello C; Pahuski M; Dube C; Guessous F; Wang B; Deveau C; Saoud K; Gallagher I; Wulfkuhle J; Schiff D; Phan S; Petricoin E; Abounader R
    Clin Cancer Res; 2019 Jan; 25(2):663-673. PubMed ID: 30201763
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inhibition of CXCL12/CXCR4 autocrine/paracrine loop reduces viability of human glioblastoma stem-like cells affecting self-renewal activity.
    Gatti M; Pattarozzi A; Bajetto A; Würth R; Daga A; Fiaschi P; Zona G; Florio T; Barbieri F
    Toxicology; 2013 Dec; 314(2-3):209-20. PubMed ID: 24157575
    [TBL] [Abstract][Full Text] [Related]  

  • 24. On-target JAK2/STAT3 inhibition slows disease progression in orthotopic xenografts of human glioblastoma brain tumor stem cells.
    Stechishin OD; Luchman HA; Ruan Y; Blough MD; Nguyen SA; Kelly JJ; Cairncross JG; Weiss S
    Neuro Oncol; 2013 Feb; 15(2):198-207. PubMed ID: 23262510
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Shisa3 brakes resistance to EGFR-TKIs in lung adenocarcinoma by suppressing cancer stem cell properties.
    Si J; Ma Y; Bi JW; Xiong Y; Lv C; Li S; Wu N; Yang Y
    J Exp Clin Cancer Res; 2019 Dec; 38(1):481. PubMed ID: 31801598
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Circular RNA-encoded oncogenic E-cadherin variant promotes glioblastoma tumorigenicity through activation of EGFR-STAT3 signalling.
    Gao X; Xia X; Li F; Zhang M; Zhou H; Wu X; Zhong J; Zhao Z; Zhao K; Liu D; Xiao F; Xu Q; Jiang T; Li B; Cheng SY; Zhang N
    Nat Cell Biol; 2021 Mar; 23(3):278-291. PubMed ID: 33664496
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Lycorine inhibits glioblastoma multiforme growth through EGFR suppression.
    Shen J; Zhang T; Cheng Z; Zhu N; Wang H; Lin L; Wang Z; Yi H; Hu M
    J Exp Clin Cancer Res; 2018 Jul; 37(1):157. PubMed ID: 30016965
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The tumor suppressor FOXO3a mediates the response to EGFR inhibition in glioblastoma cells.
    Ramis G; Villalonga-Planells R; Serra-Sitjar M; Brell M; Fernández de Mattos S; Villalonga P
    Cell Oncol (Dordr); 2019 Aug; 42(4):521-536. PubMed ID: 30980364
    [TBL] [Abstract][Full Text] [Related]  

  • 29. PTPIP51 levels in glioblastoma cells depend on inhibition of the EGF-receptor.
    Petri MK; Brobeil A; Planz J; Bräuninger A; Gattenlöhner S; Nestler U; Stenzinger A; Paradowska A; Wimmer M
    J Neurooncol; 2015 May; 123(1):15-25. PubMed ID: 25862004
    [TBL] [Abstract][Full Text] [Related]  

  • 30. TNF Inhibitor Pomalidomide Sensitizes Glioblastoma Cells to EGFR Inhibition.
    Luo Z; Wang B; Liu H; Shi L
    Ann Clin Lab Sci; 2020 Jul; 50(4):474-480. PubMed ID: 32826244
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inhibition of DYRK1A destabilizes EGFR and reduces EGFR-dependent glioblastoma growth.
    Pozo N; Zahonero C; Fernández P; Liñares JM; Ayuso A; Hagiwara M; Pérez A; Ricoy JR; Hernández-Laín A; Sepúlveda JM; Sánchez-Gómez P
    J Clin Invest; 2013 Jun; 123(6):2475-87. PubMed ID: 23635774
    [TBL] [Abstract][Full Text] [Related]  

  • 32. YAP/TAZ Transcriptional Coactivators Create Therapeutic Vulnerability to Verteporfin in EGFR-mutant Glioblastoma.
    Vigneswaran K; Boyd NH; Oh SY; Lallani S; Boucher A; Neill SG; Olson JJ; Read RD
    Clin Cancer Res; 2021 Mar; 27(5):1553-1569. PubMed ID: 33172899
    [TBL] [Abstract][Full Text] [Related]  

  • 33. AZD8931, an equipotent, reversible inhibitor of signaling by epidermal growth factor receptor, ERBB2 (HER2), and ERBB3: a unique agent for simultaneous ERBB receptor blockade in cancer.
    Hickinson DM; Klinowska T; Speake G; Vincent J; Trigwell C; Anderton J; Beck S; Marshall G; Davenport S; Callis R; Mills E; Grosios K; Smith P; Barlaam B; Wilkinson RW; Ogilvie D
    Clin Cancer Res; 2010 Feb; 16(4):1159-69. PubMed ID: 20145185
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Activity of anti-epidermal growth factor receptor monoclonal antibody C225 against glioblastoma multiforme.
    Eller JL; Longo SL; Hicklin DJ; Canute GW
    Neurosurgery; 2002 Oct; 51(4):1005-13; discussion 1013-4. PubMed ID: 12234411
    [TBL] [Abstract][Full Text] [Related]  

  • 35. EGF/EGFR upregulates and cooperates with Netrin-4 to protect glioblastoma cells from DNA damage-induced senescence.
    Li L; Huang Y; Gao Y; Shi T; Xu Y; Li H; Hyytiäinen M; Keski-Oja J; Jiang Q; Hu Y; Du Z
    BMC Cancer; 2018 Dec; 18(1):1215. PubMed ID: 30514230
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Invasion Factor ODZ1 Is Upregulated through an Epidermal Growth Factor Receptor-Induced Pathway in Primary Glioblastoma Cells.
    Velasquez C; Gutierrez O; Carcelen M; Fernandez-Luna JL
    Cells; 2024 Apr; 13(9):. PubMed ID: 38727302
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Epidermal Growth Factor (EGF) Augments the Invasive Potential of Human Glioblastoma Multiforme Cells via the Activation of Collaborative EGFR/ROS-Dependent Signaling.
    Pudełek M; Król K; Catapano J; Wróbel T; Czyż J; Ryszawy D
    Int J Mol Sci; 2020 May; 21(10):. PubMed ID: 32443749
    [TBL] [Abstract][Full Text] [Related]  

  • 38. EGFR-mediated interleukin enhancer-binding factor 3 contributes to formation and survival of cancer stem-like tumorspheres as a therapeutic target against EGFR-positive non-small cell lung cancer.
    Cheng CC; Chou KF; Wu CW; Su NW; Peng CL; Su YW; Chang J; Ho AS; Lin HC; Chen CG; Yang BL; Chang YC; Chiang YW; Lim KH; Chang YF
    Lung Cancer; 2018 Feb; 116():80-89. PubMed ID: 29413056
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Different response of human glioma tumor-initiating cells to epidermal growth factor receptor kinase inhibitors.
    Griffero F; Daga A; Marubbi D; Capra MC; Melotti A; Pattarozzi A; Gatti M; Bajetto A; Porcile C; Barbieri F; Favoni RE; Lo Casto M; Zona G; Spaziante R; Florio T; Corte G
    J Biol Chem; 2009 Mar; 284(11):7138-48. PubMed ID: 19147502
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tumor endothelial cells express epidermal growth factor receptor (EGFR) but not ErbB3 and are responsive to EGF and to EGFR kinase inhibitors.
    Amin DN; Hida K; Bielenberg DR; Klagsbrun M
    Cancer Res; 2006 Feb; 66(4):2173-80. PubMed ID: 16489018
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.